BXRXQ — Baudax Bio Share Price
0.000.00%
Last trade - 00:00- $0.29m
- $14.20m
- $1.27m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1443.08% | ||
| Return on Equity | n/a | ||
| Operating Margin | -7131.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.49 | 1.08 | 1.27 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
Directors
- Alfred Altomari NEC (62)
- Geraldine Henwood PRE (67)
- Richard Casten CFO (47)
- William Ashton IND (70)
- Arnold Baskies IND (71)
- Winston Churchill IND (80)
- Andrew Drechsler IND (49)
- Wayne Weisman IND (65)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- September 13th, 2019
- Public Since
- November 14th, 2019
- No. of Shareholders
- 9
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 43,593,082
- Address
- 490 Lapp Road, MALVERN, 19355
- Web
- https://www.baudaxbio.com/
- Phone
- +1 4843952470
- Contact
- Mike Moyer
- Auditors
- EisnerAmper LLP
Upcoming Events for BXRXQ
Q2 2024 Baudax Bio Inc Earnings Release
Q3 2024 Baudax Bio Inc Earnings Release
Similar to BXRXQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Baudax Bio share price?
As of Today at 19:33 UTC, shares in Baudax Bio are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Baudax Bio share price performed this year?
Shares in Baudax Bio last closed at $0.01 and the price had moved by -98.62% over the past 365 days. In terms of relative price strength the Baudax Bio share price has underperformed the S&P500 Index by -98.84% over the past year.
What are the analyst and broker recommendations for Baudax Bio?
The overall consensus recommendation for Baudax Bio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Baudax Bio dividend yield?
Baudax Bio does not currently pay a dividend.
Does Baudax Bio pay a dividend?
Baudax Bio does not currently pay a dividend.
When does Baudax Bio next pay dividends?
Baudax Bio does not currently pay a dividend.
How do I buy Baudax Bio shares?
To buy shares in Baudax Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Baudax Bio?
As of the previous close price of $0.01, shares in Baudax Bio had a market capitalisation of $0.31m.
Where are Baudax Bio shares listed?
Here are the trading details for Baudax Bio:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BXRXQ
What kind of share is Baudax Bio?
Based on an overall assessment of its quality, value and momentum Baudax Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Baudax Bio share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Baudax Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Baudax Bio. Over the past six months, its share price has underperformed the S&P500 Index by -59.36%.
As of the last closing price of $0.01, shares in Baudax Bio were trading -91.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Baudax Bio PE Ratio?
The Baudax Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Baudax Bio?
Baudax Bio's management team is headed by:
- Alfred Altomari - NEC
- Geraldine Henwood - PRE
- Richard Casten - CFO
- William Ashton - IND
- Arnold Baskies - IND
- Winston Churchill - IND
- Andrew Drechsler - IND
- Wayne Weisman - IND